Fun, pre-Christmas Quiz Night in aid of CCRT

Fun, pre-Christmas Quiz Night in aid of CCRT

CCRT, Events l

For a fun, pre-Christmas night out make your way to the Goat Grill, Goatstown, on Thursday December 1st for a fundraising Quiz Night in aid of CCRT! Make it your work Christmas night out!

€15 per person (€60 table of four). Tickets available from Tom Flynn email:

Great prizes up for grabs in the raffle on the night!

Huge thanks to the Flynn family for their fantastic fundraising efforts to date in memory of their Dad, Barry (RIP), and for their dedication in organising this night out in aid of CCRT and cancer research.

CCRT hosts the 9th International Symposium on Translational Research in Oncology

CCRT, Events l


Friday, 30th September, Mezzanine Suite, Herbert Park hotel
Chairs: Prof John Crown & Prof Robert Kerbel
CPD Accreditation: 6 points

Registration from 11:00

11:30-12:00 Development of immune therapies beyond PD-1 and CTLA-4 blockade
Dr Mario Sznol, Yale Cancer Centre

12:00-12:30 Clinical trials of oxygenation agents and antagonists of A2a adenosine receptors to enable tumor rejection by immunotherapies of cancer
Prof Michail Siktkovsky, Northeastern University, Boston

12:30-1:00 Talimogene laherparepvec, first approved oncolytic immunotherapy
Dr Ohrling Katarina, Amgen Inc.

1:00-1:45 Lunch, Herbert Suite

1:45-2:15 Ribociclib – mechanism of action, preclinical and early clinical development
Dr Thomas Bachelot, Centre Leon Berard, Lyon, France

2:15-2:45 Eribulin mechanisms of action: Beyond antimitotic effects to complex changes in tumour biology
Dr Bruce Littlefield, Eisai Inc.

2:45-3:15 The biology of angiogenesis and the challenge of identifying anti-angiogenesis biomarkers in oncology
Dr Annette Byrne, Royal College of Surgeons in Ireland

3:15-3:45 Implications of ‘vessel co-option’ by tumors for antiangiogenic therapy of metastatic disease
Prof Robert Kerbel, Sunnybrook Health Science Centre, Toronto

3:45-4:00 Coffee break, Herbert Suite

4:00-4:30 The PI3K pathway in cancer
Prof Bryan Hennessy, Royal College of Surgeons in Ireland

4:30-5:00 Targeting the IGF signaling network in cancer with the IGF-1/-2 ligand neutralizing antibody BI 836845 – an update
Dr Thomas Bogenrieder, Boehringer Ingelheim

5:00-5:30 Neratinib for treatment of HER2 mutant, non-amplified breast cancers
Dr Alshad Lalani, Puma Biotechnology Inc.

5:30-6:00 A brief TOR of vistusertib: translating the science into the clinic
Dr Christopher Shepherd, AstraZeneca UK Limited

Saturday 1st October, Mezzanine Suite, Herbert Park Hotel
Chairs: Prof John Crown & Prof Robert Kerbel
CPD Accreditation: 3 points

9:00-9:30 Next Generation Sequencing of FFPE samples in development cohorts and a large randomized trial (ER pos HER2 neg breast cancer).
Dr Christer Svedman, Genomic Health

9:30-10:00 Hybrid-capture based liquid biopsy allows the detection of diverse genomic alterations
Dr Judith Müller, NEO New Oncology

10:00-10.30 HER2 testing: Past and present
Prof Mike Press, University of Southern California

10:30-10:50 Coffee break, Herbert Suite

10:50-11:20 Mutant p53 as a target for the treatment of triple-negative breast cancer
Prof Joe Duffy, St Vincent’s University Hospital/University College Dublin

11:20-11:50 Targeting ATR as an attractive anti-cancer approach
Dr John Pollard, Vertex Pharmaceuticals

11:50-12:20 Talazoparib pharmacology: Clinical potential for PARP inhibition and PARP trapping
Dr Vernon Phan, Medivation Inc.

12:20-1:20 Lunch, Herbert Suite

1:20-1:50 Immune sculpting of the breast cancer genome
Prof Lajos Pusztai, Yale Cancer Center Genetics, Genomics and Epigenetics Program

1:50-2:20 Clonal diversity and genomic drivers of exceptional responses
Prof Michael Barrett, Mayo Clinic Cancer Centre, Arizona

2:20-2:50 DNA instability in solid tumours – the key to curing cancer?
Prof Ken O’Byrne, Princess Alexandra Hospital, Queensland University of Technology

2:50-3:10 Coffee break, Herbert Suite

3:10-3:40 Improving cancer therapy via CDK8/19 Mediator kinase
Prof Igor Roninson, University of South Carolina

3:40-4:10 The potential of inecalcitol, a vitamin D receptor agonist, in hematologic malignancies
Dr Remi Delansorne, Hybrigenics

4:10-4:40 Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer
Dr Neil O’Brien, Department of Medicine, UCLA

4:40-5:10 Development of palbociclib from pre-clinical assessment to global registration: A paradigm for development of CDK 4/6 inhibitors
Dr Rich Finn, Geffen School of Medicine, UCLA